Tumor Biology

, Volume 36, Issue 6, pp 4495–4500 | Cite as

RETRACTED ARTICLE: Urinary parameters predictive and electrolyte disturbances of cisplatin-induced acute renal associated with cancer as a critical target of the chemotherapeutic agent in patients with solid tumors

  • Behnam Pedram
  • Ahmad Taghavi Moghadam
  • Zahra Kamyabi-Moghaddam
  • Omid Mavedati
  • Babak Abbas Beigi
  • Adel Khodaei Sharabiyani
  • Ali Bashiri Dezfuli
  • Soheil Khalili
  • Ali Mohammad Bahrami
  • Alireza Nasoori
Research Article


Cisplatin (CP) is a remarkably effective Pt-based anticancer drug, but it also exhibits severe toxic side effects, including nephrotoxicity and ototoxicity, and CP nephrotoxicity is a major constraint for the treatment of solid tumors. This study was designed to evaluate the electrolyte and biochemical changes in dogs with acute kidney injury (acute renal failure) following administration of CP as a chemotherapeutic agent to exhibit broad efficacy in solid tumors. A total of 10 adult male dogs were selected (treated dogs = 7 and control dogs = 3). Cisplatin-treated animals were received 0.75 mg/kg via intravenous for 5 consecutive days. Urine and blood samples on days 0 (pre-dosing), 1, 2, 3, 4, 7, 10, 14, and 28 (post-dosing) were collected. For tracking the signs of toxicity with cisplatin, clinical examination was performed for 2 times a day. Serum samples were assayed urea, creatinine, sodium, chloride, potassium, calcium, phosphorus, and urine samples were used to measure creatinine. Serum creatinine levels indicating renal function (glomerular filtration rate) was 0.66 and 0.94 mg/dL in day 0, respectively, in treatment and control animals. After day 2, a significant change in creatinine was observed in treatment animals. On the end day of the study control and treatments, creatinine was measured with mean of 1.35 and 1.00 mg/dL, respectively. Electrolyte disturbances were observed after several days of cisplatin administration including changes in levels of sodium, potassium, phosphorus, calcium, and chloride. Clinical observations also identified CP toxicity. This study for the first time showed that compensation electrolyte abnormalities in dogs following administration of cisplatin is essential to prevent deaths by daily monitoring and measurement of electrolytes in patients. This may be advantageous if repetitive cycles of chemotherapy or subsequent administration of high dose chemotherapy were planned.


Cisplatin Dog Electrolyte disturbance Urea Creatinine 



The authors thank the staff of the department of pathology for their valuable technical assistance.

Conflicts of interest



  1. 1.
    Frezza M, Hindo S, Chen D, Davenport A, Schmitt S, Tomco D, et al. Novel metals and metal complexes as platforms for cancer therapy. Curr Pharm Des. 2010;16(16):1813–25.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Aoki K, Murayama K. Nucleic acid-metal ion interactions in the solid state. Met Ions Life Sci. 2012;10:43–102.CrossRefPubMedGoogle Scholar
  3. 3.
    Desoize B, Madoulet C. Particular aspects of platinum compounds used at present in cancer treatment. Crit Rev Oncol Hematol. 2002;42(3):317–25.CrossRefPubMedGoogle Scholar
  4. 4.
    Che CM, Siu FM. Metal complexes in medicine with a focus on enzyme inhibition. Curr Opin Chem Biol. 2010;14(2):255–61.CrossRefPubMedGoogle Scholar
  5. 5.
    Chen D, Milacic V, Frezza M, Dou QP. Metal complexes, their cellular targets and potential for cancer therapy. Curr Pharm Des. 2009;15(7):777–91.CrossRefPubMedGoogle Scholar
  6. 6.
    Zhang J, Wang L, Xing Z, Liu D, Sun J, Li X, et al. Status of bi- and multi-nuclear platinum anticancer drug development. Anticancer Agents Med Chem. 2010;10(4):272–82.CrossRefPubMedGoogle Scholar
  7. 7.
    Shah N, Dizon DS. New-generation platinum agents for solid tumors. Future Oncol. 2009;5(1):33–42.CrossRefPubMedGoogle Scholar
  8. 8.
    Momekov G, Ferdinandov D, Bakalova A, Zaharieva M, Konstantinov S, Karaivanova M. In vitro toxicological evaluation of a dinuclear platinum (II) complex with acetate ligands. Arch Toxicol. 2006;80(9):555–60.CrossRefPubMedGoogle Scholar
  9. 9.
    Daugaard G, Abildgaard U, Larsen S, Holstein-Rathlou NH, Amtorp O, Olesen HP, et al. Functional and histopathological changes in dog kidneys after administration of cisplatin. Ren Physiol. 1987;10(1):54–64.PubMedGoogle Scholar
  10. 10.
    Daugaard G, Abildgaard U, Holstein-Rathlou NH, Amtorp O, Leyssac PP. Acute and subacute hemodynamic and tubular effect of cisplatin in dogs. Contrib Nephrol. 1987;56:7–11.CrossRefPubMedGoogle Scholar
  11. 11.
    Rebecca AA, Matthew DH, Trevor WH. The discovery and development of cisplatin. J Chem Edu. 2006;83:724–8.Google Scholar
  12. 12.
    Cunninqham SG. Fluid and electrolyte disturbances associated with cancer and its treatment. Nurs Clin North Am. 1982;17(4):579–93.Google Scholar
  13. 13.
    Hartmann JT, Fels LM, Knop S, Stolt H, Kanz L, Bokemeyer C. A randomized trial comparing the nephrotoxicity of cisplatin/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumors. Invest New Drugs. 2000;18(3):281–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Hartmann JT, Lipp HP. Toxicity of platinum compounds. Expert Opin Pharmacother. 2003;4(6):889–901.CrossRefPubMedGoogle Scholar
  15. 15.
    Sastry J, Kellie SJ. Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine. Pediatr Hematol Oncol. 2005;22(5):441–5.CrossRefPubMedGoogle Scholar
  16. 16.
    Arany I, Safirstein RL. Cisplatin nephrotoxicity. Semin Nephrol. 2003;23(5):460–4.CrossRefPubMedGoogle Scholar
  17. 17.
    Boulikas T. Poly(ADP-ribose) synthesis in blocked and damaged cells and its relation to carcinogenesis. Anticancer Res. 1992;12(3):885–98.PubMedGoogle Scholar
  18. 18.
    Miller RP, Tadagavadi RK, Ramesh G, Reeves WB. Mechanisms of cisplatin nephrotoxicity. Toxins (Basel). 2010;2(11):2490–518.CrossRefGoogle Scholar
  19. 19.
    Safirstein R, Miller P, Guttenplan JB. Uptake and metabolism of cisplatin by rat kidney. Kidney Int. 1984;25(5):753–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Endo T, Kimura O, Sakata M. Carrier-mediated uptake of cisplatin by the OK renal epithelial cell line. Toxicology. 2000;146:187–95.CrossRefPubMedGoogle Scholar
  21. 21.
    Kolb R, Ghazi M, Barfuss D. Inhibition of basolateral transport and cellular accumulation of cDDP and N-acetyl-L-cysteine-cDDP by TEA and PAH in the renal proximal tubule. Cancer Chemother Pharmacol. 2003;51:132–8.PubMedGoogle Scholar
  22. 22.
    Olivero OA, Chang PK, Lopez-Larraza DM, Semino-Mora MC, Poirier MC. Preferential formation and decreased removal of cisplatin-DNA adducts in Chinese hamster ovary cell mitochondrial DNA as compared to nuclear DNA. Mutat Res. 1997;391(1–2):79–86.CrossRefPubMedGoogle Scholar
  23. 23.
    Cullen KJ, Yang Z, Schumaker L, Guo Z. Mitochondria as a critical target of the chemotheraputic agent cisplatin in head and neck cancer. J Bioenerg Biomembr. 2007;39(1):43–50.CrossRefPubMedGoogle Scholar
  24. 24.
    Lebedeva MA, Eaton JS, Shadel GS. Loss of p53 causes mitochondrial DNA depletion and altered mitochondrial reactive oxygen species homeostasis. Biochim Biophys Acta Bioenerg. 2009;1787:328–34.CrossRefGoogle Scholar
  25. 25.
    Yoshida Y, Izumi H, Torigoe T, Ishiguchi H, Itoh H, Kang D, et al. P53 physically interacts with mitochondrial transcription factor A and differentially regulates binding to damaged DNA. Cancer Res. 2003;63(13):3729–34.PubMedGoogle Scholar
  26. 26.
    Jiang M, Wei Q, Pabla N, Dong G, Wang CY, Yang T, Smith SB, Dong Z. Effects of hydroxyl radical scavenging on cisplatin-induced p53 activation, tubular cell apoptosis and nephrotoxicity. Biochem Pharmacol. 2007 1;73(9):1499–510.Google Scholar
  27. 27.
    Pabla N, Huang S, Mi QS, Daniel R, Dong Z. ATR-Chk2 signaling in p53 activation and DNA damage response during cisplatin-induced apoptosis. J Biol Chem. 2008;283(10):6572–83.CrossRefPubMedGoogle Scholar
  28. 28.
    Price PM, Yu F, Kaldis P, Aleem E, Nowak G, Safirstein RL, et al. Dependence of cisplatin-induced cell death in vitro and in vivo on cyclin-dependent kinase 2. J Am Soc Nephrol. 2006;17(9):2434–42.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Pan H, Mukhopadhyay P, Rajesh M, Patel V, Mukhopadhyay B, Gao B, et al. Cannabidiol attenuates cisplatin-induced nephrotoxicity by decreasing oxidative/nitrosative stress, inflammation, and cell death. J Pharmacol Exp Ther. 2009;328(3):708–14.CrossRefPubMedGoogle Scholar
  30. 30.
    Mashhadi MA, Heidari Z, Zakeri Z. Mild hypomagnesemia as the most common cisplatin nephropathy in Iran. Iran J Kidney Dis. 2013;7(1):23–7.PubMedGoogle Scholar
  31. 31.
    Panichpisal K, Angulo-Pernett F, Selhi S, Nugent KM. Gitelman-like syndrome after cisplatin therapy: a case report and literature review. BMC Nephrol. 2006;7:10.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Arany I, Safirstein RL. Cisplatin nephrotoxicity. Semin Nephrol. 2003;23:460–4.CrossRefPubMedGoogle Scholar
  33. 33.
    Forterre S, Raila J, Schweigert FJ. Protein profiling of urine from dogs with renal disease using protein chip analysis. J Vet Diagn Invest. 2004;16:271–7.CrossRefPubMedGoogle Scholar
  34. 34.
    Sharkey LC, Berzina I, Ferasin L, Tobias AH, Lulich JP, Hegstad-Davies RL. Evaluation of serum cardiac troponin I concentration in dogs with renal failure. J Am Vet Med Assoc. 2009;234(6):767–70.CrossRefPubMedGoogle Scholar
  35. 35.
    Uechi M, Nogami Y, Terui H, Nakayama T, Ishikawa R, Wakao Y, et al. Evaluation of urinary enzymes in dogs with early renal disorder. J Vet Med Sci. 1994;56(3):555–6.CrossRefPubMedGoogle Scholar
  36. 36.
    McDuffie JE, Sablad M, Ma J, Snook S. Urinary parameters predictive of cisplatin-induced acute renal injury in dogs. Cytokine. 2010;52(3):156–62.CrossRefPubMedGoogle Scholar
  37. 37.
    Schaeppi U, Heyman IA, Fleischman RW, Rosenkrantz H, Ilievski V, Phelan R. Cis-Dichlorodiammineplatinum(II) (NSC-119 875): preclinical toxicologic evaluation of intravenous injection in dogs, monkeys and mice. Toxicol Appl Pharmacol. 1973;25:230–41.CrossRefPubMedGoogle Scholar
  38. 38.
    Llach F, Bover J. Renal osteodystrophies. In Brenner B.M. (Ed.), Brenner and Rector’s the kidney (6th ed., pp. 2103–2135). Philadelphia: W.B. Saunders. 2000.Google Scholar
  39. 39.
    Hrusks KA, Teitelbaum SL. Renal osteodystrophy. N Engl J Med. 1995;333:166–74.CrossRefGoogle Scholar
  40. 40.
    Brady HR, Brenner BM, Clarkson MR. Acute renal failure. In Brenner B.M. (Ed.), Brenner and Rector’s the kidney (6th ed., pp. 1201–1247). Philadelphia: W.B. Saunders. 2000.Google Scholar
  41. 41.
    Guyton A, Hall JE. Textbook of medical physiology (10th ed., pp. 369–371, 373–378). Philadelphia: W.B. Saunders. 2000.Google Scholar
  42. 42.
    Santoso JT, Lucci JA, Coleman RL, Schafer I, Hannigan EV. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial. Cancer Chemother Pharmacol. 2003;52(1):13–8.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Behnam Pedram
    • 1
  • Ahmad Taghavi Moghadam
    • 2
  • Zahra Kamyabi-Moghaddam
    • 3
    • 9
  • Omid Mavedati
    • 4
  • Babak Abbas Beigi
    • 5
  • Adel Khodaei Sharabiyani
    • 6
  • Ali Bashiri Dezfuli
    • 7
  • Soheil Khalili
    • 6
  • Ali Mohammad Bahrami
    • 8
  • Alireza Nasoori
    • 6
  1. 1.Department of Pathobiology, Susangerd BranchIslamic Azad UniversitySusangerdIran
  2. 2.Razi Vaccine and Serum Research Institute, Ahwaz BranchAhwazIran
  3. 3.Department of Medicine II, Klinikum rechts der IsarTU MuenchenMunichGermany
  4. 4.Department of Clinical Science, Faculty of Veterinary MedicineUniversity of TehranTehranIran
  5. 5.Department of Medical HistoryMazandaran University of Medical SciencesSariIran
  6. 6.Graduate of Faculty of Veterinary MedicineIslamic Azad University, Karaj BranchKarajIran
  7. 7.Department of Toxicology, Faculty of Veterinary MedicineUniversity of TehranTehranIran
  8. 8.Faculty of Para Veterinary MedicineIlam UniversityIlamIran
  9. 9.Department of Pathology, Faculty of Veterinary MedicinesTehran UniversityTehranIran

Personalised recommendations